Blocking Dopamine D2 Receptors by Haloperidol Curtails the Beneficial Impact of Calorie Restriction on the Metabolic Phenotype of High-Fat Diet Induced Obese Mice

Journal of Neuroendocrinology

Volumn 23, Issue 2, 2011, Pages 158-167

  De Leeuw Van Weenen, J E ^a   Auvinen, H E ^a   Parlevliet, E T ^a   Coomans, C P ^a   Schroder Van Der Elst J P ^a   Meijer, O C ^b   Pijl, H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Calorie restriction; Dopamine receptor D2; High fat diet; Insulin resistance; Mice

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; DOPAMINE RECEPTOR BLOCKING AGENT; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC RESTRICTION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FOOD INTAKE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HYPOTHALAMUS; INSULIN SENSITIVITY; LIPID DIET; MALE; METABOLISM; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; ANIMAL; BODY WEIGHT; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; EATING; FAT INTAKE; INSULIN RESISTANCE; METHODOLOGY; MOUSE MUTANT;

ANIMALS; BODY WEIGHT; CALORIC RESTRICTION; DIETARY FATS; DOPAMINE ANTAGONISTS; EATING; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HALOPERIDOL; HYPOTHALAMUS; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; RECEPTORS, DOPAMINE D2;

EID: 78651086857     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2010.02092.x     Document Type: Article

References (70)

1. Weindruch R, Sohal RS. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N Engl J Med 1997; 337: 986-994.
2. Blackwell BN, Bucci TJ, Hart RW, Turturro A. Longevity, body weight, and neoplasia in ad libitum-fed and diet-restricted C57BL6 mice fed NIH-31 open formula diet. Toxicol Pathol 1995; 23: 570-582.
3. Hursting SD, Perkins SN, Brown CC, Haines DC, Phang JM. Calorie restriction induces a p53-independent delay of spontaneous carcinogenesis in p53-deficient and wild-type mice. Cancer Res 1997; 57: 2843-2846.
4. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA 2004; 101: 6659-6663.
5. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1287-1293.
6. Markovic TP, Jenkins AB, Campbell LV, Furler SM, Kraegen EW, Chisholm DJ. The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM. Diabetes Care 1998; 21: 687-694.
7. Jazet IM, Schaart G, Gastaldelli A, Ferrannini E, Hesselink MK, Schrauwen P, Romijn JA, Maassen JA, Pijl H, Ouwens DM, Meinders AE. Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients. Diabetologia 2008; 51: 309-319.
8. Man ZW, Hirashima T, Mori S, Kawano K. Decrease in triglyceride accumulation in tissues by restricted diet and improvement of diabetes in Otsuka Long-Evans Tokushima fatty rats, a non-insulin-dependent diabetes model. Metabolism 2000; 49: 108-114.
9. Park S, Komatsu T, Hayashi H, Yamaza H, Chiba T, Higami Y, Kuramoto K, Shimokawa I. Calorie restriction initiated at middle age improved glucose tolerance without affecting age-related impairments of insulin signaling in rat skeletal muscle. Exp Gerontol 2006; 41: 837-845.
10. Roth GS, Ingram DK, Joseph JA. Delayed loss of striatal dopamine receptors during aging of dietarily restricted rats. Brain Res 1984; 300: 27-32.
11. 3H] spiperone) autoradiography. Synapse 2008; 62: 50-61.
12. Erdos B, Broxson CS, Landa T, Scarpace PJ, Leeuwenburgh C, Zhang Y, Tumer N. Effects of life-long caloric restriction and voluntary exercise on age-related changes in levels of catecholamine biosynthetic enzymes and angiotensin II receptors in the rat adrenal medulla and hypothalamus. Exp Gerontol 2007; 42: 745-752.
13. Carr KD, Tsimberg Y, Berman Y, Yamamoto N. Evidence of increased dopamine receptor signaling in food-restricted rats. Neuroscience 2003; 119: 1157-1167.
14. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995; 83: 1197-1209.
15. Meguid MM, Fetissov SO, Varma M, Sato T, Zhang L, Laviano A, Rossi-Fanelli F. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000; 16: 843-857.
16. Meier AH, Cincotta AH. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev 1996; 4: 464-487.
17. Nestler EJ. Hard target: understanding dopaminergic neurotransmission. Cell 1994; 79: 923-926.
18. Yang ZJ, Meguid MM. LHA dopaminergic activity in obese and lean Zucker rats. Neuroreport 1995; 6: 1191-1194.
19. Lemierre S, Rouch C, Nicolaidis S, Orosco M. Combined effect of obesity and aging on feeding-induced monoamine release in the rostromedial hypothalamus of the Zucker rat. Int J Obes Relat Metab Disord 1998; 22: 993-999.
20. Orosco M, Rouch C, Meile MJ, Nicolaidis S. Spontaneous feeding-related monoamine changes in rostromedial hypothalamus of the obese Zucker rat: a microdialysis study. Physiol Behav 1995; 57: 1103-1106.
21. Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a 'thrifty' genotype underlying the metabolic syndrome? Eur J Pharmacol 2003; 480: 125-131.
22. Fetissov SO, Meguid MM, Sato T, Zhang LH. Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. Am J Physiol Regul Integr Comp Physiol 2002; 283: R905-R910.
23. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS. Brain dopamine and obesity. Lancet 2001; 357: 354-357.
24. Baptista T, Araujo dB, Ying Kin NM, Beaulieu S, Walker D, Joober R, Lalonde J, Richard D. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 2002; 957: 144-151.
25. Baptista T, Parada M, Hernandez L. Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 1987; 27: 399-405.
26. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl 1): 1-93.
27. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M, Bergman RN. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54: 862-871.
28. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154-1161.
29. Kok P, Roelfsema F, Frolich M, van Pelt J, Stokkel MP, Meinders AE, Pijl H. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab 2006; 291: E1038-E1043.
30. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 1999; 69: 160-166.
31. Kuo DY. Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats. J Biomed Sci 2002; 9: 126-132.
32. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001; 156: 117-154.
33. Metzger KL, Shoemaker JM, Kahn JB, Maxwell CR, Liang Y, Tokarczyk J, Kanes SJ, Hans M, Lowman AM, Dan N, Winey KI, Swerdlow NR, Siegel SJ. Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. Psychopharmacology (Berl) 2007; 190: 201-211.
34. Voshol PJ, Jong MC, Dahlmans VE, Kratky D, Levak-Frank S, Zechner R, Romijn JA, Havekes LM. In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake. Diabetes 2001; 50: 2585-2590.
35. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press, 2001.
36. Escriva F, Gavete ML, Fermin Y, Perez C, Gallardo N, Alvarez C, Andres A, Ros M, Carrascosa JM. Effect of age and moderate food restriction on insulin sensitivity in Wistar rats: role of adiposity. J Endocrinol 2007; 194: 131-141.
37. Barzilai N, Banerjee S, Hawkins M, Chen W, Rossetti L. Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. J Clin Invest 1998; 101: 1353-1361.
38. Okauchi N, Mizuno A, Yoshimoto S, Zhu M, Sano T, Shima K. Is caloric restriction effective in preventing diabetes mellitus in the Otsuka Long Evans Tokushima fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus? Diabetes Res Clin Pract 1995; 27: 97-106.
39. Zheng Y, Zhang W, Pendleton E, Leng S, Wu J, Chen R, Sun XJ. Improved insulin sensitivity by calorie restriction is associated with reduction of ERK and p70S6K activities in the liver of obese Zucker rats. J Endocrinol 2009; 203: 337-347.
40. Anson RM, Guo Z, de Cabo R, Iyun T, Rios M, Hagepanos A, Ingram DK, Lane MA, Mattson MP. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc Natl Acad Sci USA 2003; 100: 6216-6220.
41. Jazet IM, Pijl H, Frolich M, Romijn JA, Meinders AE. Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin. Metabolism 2005; 54: 705-712.
42. Halberg N, Henriksen M, Soderhamn N, Stallknecht B, Ploug T, Schjerling P, Dela F. Effect of intermittent fasting and refeeding on insulin action in healthy men. J Appl Physiol 2005; 99: 2128-2136.
43. Liang Y, Jetton TL, Lubkin M, Meier AH, Cincotta AH. Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell Mol Life Sci 1998; 54: 703-711.
44. Jetton TL, Liang Y, Cincotta AH. Systemic treatment with sympatholytic dopamine agonists improves aberrant beta-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice. Metabolism 2001; 50: 1377-1384.
45. Pezzarossa A, Vescovi PP, Cervigni C, Angelini O, Cimicchi MC, Capretti L, Campana G, Butturini U. Effect of domperidone on the release of insulin after intravenous glucose load in man. J Endocrinol Invest 1986; 9: 383-388.
46. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006; 186: 572-578.
47. Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population. Schizophr Res 2009; 107: 115-121.
48. Morton GJ. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol 2007; 583: 437-443.
49. Han M, Huang XF, Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol 2009; 12: 941-952.
50. Kabbani N, Levenson R. Antipsychotic-induced alterations in D2 dopamine receptor interacting proteins within the cortex. Neuroreport 2006; 17: 299-301.
51. Hurley MJ, Stubbs CM, Jenner P, Marsden CD. Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain. Psychopharmacology (Berl) 1996; 128: 362-370.
52. Smith GC, Chaussade C, Vickers M, Jensen J, Shepherd PR. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 2008; 51: 2309-2317.
53. Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC, Barr AM. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 945-954.
54. Lin EJ, Lee NJ, Slack K, Karl T, Duffy L, O'brien E, Matsumoto I, Dedova I, Herzog H, Sainsbury A. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology 2006; 51: 1129-1136.
55. Simon VM, Parra A, Minarro J, Arenas MC, Vinader-Caerols C, Aguilar MA. Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. Eur Neuropsychopharmacol 2000; 10: 159-164.
56. Wiley JL, Evans RL. Evaluation of age and sex differences in locomotion and catalepsy during repeated administration of haloperidol and clozapine in adolescent and adult rats. Pharmacol Res 2008; 58: 240-246.
57. Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, Lynch CJ. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry 2010; doi:10.1038/mp.2010.33.
58. Stuart CA, Shangraw RE, Prince MJ, Peters EJ, Wolfe RR. Bed-rest-induced insulin resistance occurs primarily in muscle. Metabolism 1988; 37: 802-806.
59. Alibegovic AC, Hojbjerre L, Sonne MP, van Hall G, Stallknecht B, Dela F, Vaag A. Impact of 9 days of bed rest on hepatic and peripheral insulin action, insulin secretion, and whole-body lipolysis in healthy young male offspring of patients with type 2 diabetes. Diabetes 2009; 58: 2749-2756.
60. Sonne MP, Alibegovic AC, Hojbjerre L, Vaag A, Stallknecht B, Dela F. Effect of 10 days of bedrest on metabolic and vascular insulin action: a study in individuals at risk for type 2 diabetes. J Appl Physiol 2010; 108: 830-837.
61. King DS, Dalsky GP, Clutter WE, Young DA, Staten MA, Cryer PE, Holloszy JO. Effects of lack of exercise on insulin secretion and action in trained subjects. Am J Physiol 1988; 254: E537-E542.
62. McCoy M, Proietto J, Hargreves M. Effect of detraining on GLUT-4 protein in human skeletal muscle. J Appl Physiol 1994; 77: 1532-1536.
63. Hruska RE. Modulatory role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonists. Brain Res Bull 1986; 16: 331-339.
64. Xu R, Parlow AF, Wang Y. The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor. Brain Res 2002; 939: 95-99.
65. Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ. Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 1980; 51: 242-246.
66. Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M, Tuzcu S. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary 2009; 12: 330-334.
67. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007; 32: 289-297.
68. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, Remington G. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 2008; 28: 494-499.
69. Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, Nobrega J, Remington G. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res 2009; 108: 127-133.
70. Garcia-Tornadu I, Ornstein AM, Chamson-Reig A, Wheeler MB, Hill DJ, Arany E, Rubinstein M, Becu-Villalobos D. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010; 151: 1441-1450.